A comprehensive insight into the effect of glutamine supplementation on metabolic variables in diabetes mellitus: a systematic review

Hamed Jafari-Vayghan1,2, Parisa Varshosaz3, Fatemeh Hajizadeh-Sharafabad4, Hamid Reza Razmi1, Mahdi Amirpour1, Omid Mohammad Tavakoli-Rouzbehani1, Mohammad Alizadeh5* and Vahid Maleki1*©

Abstract
Diabetes mellitus is one of the most important threats to human health in the twenty-first century. The use of complementary and alternative medicine to prevent, control, and reduce the complications of diabetes mellitus is increasing at present. Glutamine amino acid is known as a functional food. The purpose of this systematic review is to determine the potential role of glutamine supplementation on metabolic variables in diabetes mellitus. For this review, PubMed, SCOPUS, Embase, ProQuest, and Google Scholar databases were searched from inception through April 2020. All clinical trial and animal studies assessing the effects of glutamine on diabetes mellitus were eligible for inclusion. 19 studies of 1482 articles met the inclusion criteria. Of the 19 studies, nine studies reported a significant increase in serum GLP-1 levels. Also, eight studies showed reducing in serum levels of fasting blood sugar, four studies reducing in postprandial blood sugar, and triglyceride after glutamine supplementation. Although glutamine resulted in a significant increase in insulin production in seven studies, the findings on Hb-A1c levels were inconclusive. In addition to, despite of the results was promising for the effects of glutamine on weight changes, oxidative stress, and inflammation, more precise clinical trials are needed to obtain more accurate results. In conclusion, glutamine supplementation could improve glycemic control and levels of incretins (such as GLP-1 and GIP) in diabetes mellitus. However, more studies are needed for future studies.

Keywords: Glutamine, Diabetes mellitus, Glycemic control, GLP-1, Oxidative stress, Systematic review

Introduction
Diabetes mellitus is one of the major threats to human health in the twenty-first century [1]. The prevalence of this disease is rising dramatically in the world, and the global prevalence of diabetes is about 8.8% (415 million) in 2015 [2]. It is estimated that the prevalence of this disease will reach 439 million by 2030 and 642 million by 2040 [3]. Approximately 85% of patients with diabetes mellitus have Type 2 diabetes mellitus (T2DM), which can be a result of genetic predisposition, environmental factors, or a combination of these two [4]. Diabetes mellitus refers to metabolic diseases which are characterized by hyperglycemia that develops as a result of impairment in insulin secretion, insulin action, or both [5, 6]. Chronic hyperglycemia can cause macrovascular complications such as coronary artery disease, peripheral vascular disease, and cerebrovascular disease, and microvascular complications, including retinopathy,
nephropathy, and neuropathy [7]. Also, chronic hyperglycemia increased inflammation and oxidative stress that play an important central role in the pathogenesis of diabetes complications [8].

Recently, the use of complementary therapy to improve and reduce the symptoms of diabetes mellitus, along with drug therapy and reduced drug dosage, have increased in use [9]. Glutamine, an α-amino acid that is used in the biosynthesis of proteins, is both non-essential and conditionally essential in humans. The body can usually synthesize sufficient amounts of glutamine, but in some instances of stress, the body's demand for glutamine increases, and glutamine must be obtained from the diet [10, 11].

Glutamine is the physiological precursor of arginine for the production of nitric oxide (NO), whose creation in β-cells potentiates insulin secretion [12]. Furthermore, glutamine creates the main source of glutamate for the production of glutathione, which is essential in reducing oxidative stress, which eventually results in maintaining inflammatory processes within β-cells in diabetes [12]. Moreover, in improving the glucose profile, L-glutamine has a positive effect on glucose oxidation and insulin resistance [13]. Oral L-glutamine enhances the circulation of gastrointestinal incretin hormones (glucagon-like peptide-1 (GLP-1) and stimulated insulin release as well as reduced (postprandial) glycemia in diabetes mellitus [14, 15].

Although several studies have shown positive effects of glutamine supplementation on metabolic variables in diabetes mellitus, there is no systematic review that summarizes the results of these studies. This study aims to evaluate the effects of glutamine on metabolic variables in diabetes Mellitus and to determine possible directions for future studies.

Method

Search strategy
To find relevant publications earlier than April 2020, two independent investigators performed a literature search in PubMed, SCOPUS, Embase, ProQuest, and Google Scholar electronic databases using following keywords: “glutamine” OR “L–glutamine” OR “glutamine supplementation” OR “glutamine dipeptides” AND “diabetes mellitus” or “type 2 diabetes” or “type II diabetes” or “Type 1 diabetes” or “type 1 diabetes” or “diabetic” or “T2DM” or “T1DM” or “noninsulin-dependent diabetes mellitus” or “insulin-dependent diabetes mellitus” or “NIDDM” or “IDDM” or “hyperglycemia” or “diabetic” or “FBS” or “fasting blood sugar” or “glycemic outcomes” or “fasting blood glucose” or “HOMA-IR” or “B-cell function” or “insulin” or “glucose” or “glycemic” or “hyperglycemic”. Reference lists and related records were manually reviewed. The search was limited to English language articles up through April 2020. This study was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol for reporting systematic reviews and meta-analyses. The protocol for this review was registered in the PROSPERO database under registration number CRD42018090829.

Eligibility criteria
All clinical trial and animal studies assessing the effects of glutamine on metabolic variables (e.g., glycemic status, incretin hormones, lipid profile, oxidative stress and inflammation biomarkers) in diabetes mellitus were eligible for inclusion; exclusion criteria were (1) in vitro models, and (2) studies published in non-English language journals.

Data extraction
Data extraction was conducted independently by two investigators using a standardized data collection form. The following information was also obtained from each study: first author, year of publication, country of origin, age range, sample size, daily dose, duration of intervention, and principal outcome. The quality of the included studies was assessed by a third reviewer using primary data extraction. Finally, the reviewers discussed articles to reach an agreement.

Quality assessment
Two independent researchers analyzed the quality of eligible studies. Randomized control trials were evaluated using Physiotherapy Evidence Database [16] (PEDro) scale, and the score are represented in Table 1.

Results
A flow diagram of the study selection is summarized in Fig. 1. A total of 1482 articles were retrieved, of which 294 were duplicates, resulting in 1188 non-duplicated publications. Of these, 1167 articles did not meet the inclusion criteria and were excluded. Finally, 20 articles met the inclusion criteria for this review. The characteristics of the selected studies are provided in Tables 2 and 3.
Table 1  Assessment quality using the PEDro scale for randomized clinical trials

| Items                  | Chang et al. | Mansour et al. | Samocha-Bonet et al. | Takeuti et al. | Samocha-Bonet et al. | Greenfield et al. | Samocha-Bonet et al. | Lomivorotov et al. | Torres-Santiago et al. | Meek et al. |
|------------------------|--------------|----------------|----------------------|----------------|----------------------|------------------|----------------------|---------------------|------------------------|-------------|
| 1. Eligibility criteria| N            | Y              | Y                    | N              | Y                    | Y                | Y                    | Y                   | Y                      | N           |
| 2. Random allocation   | Y            | Y              | Y                    | N              | Y                    | Y                | Y                    | Y                   | Y                      | Y           |
| 3. Concealed allocation| N            | N              | N                    | N              | N                    | N                | N                    | Y                   | N                      | N           |
| 4. Similar at baseline| Y            | Y              | Y                    | Y              | Y                    | Y                | Y                    | Y                   | Y                      | Y           |
| 5. Blinding subjects   | Y            | Y              | N                    | Y              | N                    | N                | Y                    | Y                   | Y                      | Y           |
| 6. Blinding therapists  | N            | Y              | N                    | N              | N                    | N                | N                    | Y                   | Y                      | Y           |
| 7. Blinding assessors  | N            | N              | N                    | N              | N                    | N                | N                    | N                   | N                      | N           |
| 8. Adequate follow up  | Y            | Y              | Y                    | N              | Y                    | Y                | Y                    | Y                   | Y                      | Y           |
| 9. Intention to treat analysis | N | N | N | N | Y | N | Y | Y | N | N |
| 10. Between group statistical comparison | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 11. Point estimate/measure of variability | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Score total            | 6/10         | 7/10           | 5/10                 | 3/10           | 8/10                 | 4/10             | 6/10                 | 9/10                | 7/10                   | 7/10 |

Y, contemplated item; N, no contemplated item

* Item 1 does not contribute to the total score
and one was conducted on the obese and diabetic subject [15]. Also, two studies examined the glutamine effect on diabetes type 1 patients [31, 32]. Glutamine was generally supplemented by diluting in water and taken as a drink. Five human studies gave glutamine to subjects, which were overweight or obese [14, 15, 26–28]. No oral hypoglycemic agents were taken by the subject of Greenfield et al. study [15], while others used no other hypoglycemic agents except for metformin in a stable dose [14, 28]. The characteristics of included studies are outlined in Tables 2 and 3.

**Glutamine, weight change in diabetes mellitus**

**Animal studies**

Three studies investigated the effect of glutamine on weight change in animals. Weight in rats decreased after
Table 2  Characteristics of animal studies that reported the effects of glutamine on metabolic variables in diabetes mellitus

| Author, year, place          | Models                                                                 | Daily dose          | Duration | Main Outcomes                                                                 |
|-----------------------------|------------------------------------------------------------------------|---------------------|----------|-------------------------------------------------------------------------------|
| Alba-Loureiro et al., Brazil, 2009 [23] | Wistar rats were divided into four groups: 1. Control, 2. Control + glutamine, 3. Diabetic, 4. Diabetic + glutamine | 1000 mg/kg          | 15 days | No significant change Fasting Blood glucose, TC, body weight gain Significant decrease TG  |
|                             |                                                                        |                     |          |                                                                                |
| Tsai et al., Taiwan 2011 [20] | Rats divided into three groups: 1. Normal control, 2. Diabetic fed with a common semi purified diet, 3. Identical diet with glutamine | 25% of total amino acid nitrogen | 6 weeks | No significant change Fasting Plasma glucose Significant increase GSH/GSSG |
| Tsai et al., Taiwan, 2012 [19] | Rats divided into three groups: 1. Normal control, 2. Diabetic fed with a common semi purified diet, 3. Identical diet with glutamine | 25% of total amino acid nitrogen | 8 weeks | Significant decrease GPx, SOD, Significant increase TAC, catalase, GRd, GSSG No significant change HDL, TG, LDL, TC, fasting glucose |
| Tsia, Taiwan, 2012 [22]     | Rats divided into three groups: 1. Normal control, 2. Diabetic fed with a common semi purified diet, 3. Identical diet with glutamine | 25% of total amino acid nitrogen | 8 weeks | Significant increase GSH Significant decrease CRP, II-6, IL-23, MCP-1 No significant change Fasting blood Glucose, TGF-β, TNF-α, IL-17A |
| Badole et al., India, 2013 [18] | Rats divided into six groups: 1. Nondiabetic, 2. Diabetic control, 3. Sitagliptin (5 mg/kg), 4. Glutamine 250 mg/kg, 5. Glutamine 500 mg/kg, 6. Glutamine 1000 mg/kg | 250–500-1000 mg/kg | 8 weeks | Significant decrease MDA, fasting blood glucose, LDL, TC, TG Significant increase Plasma and pancreatic insulin, increased GLP-1, amide secretion, GSH, SOD, GPx (only the highest dose), HDL |
| Badole et al., India, 2013 [18] | Rats divided into four groups: 1. Non-diabetic, 2. Diabetic control, 3. Sitagliptin + cycloarten-23-ene-3b, 25-diol (1 mg/kg) 4. Sitagliptin (5 mg/kg, p.o.) + L-glutamine (1000 mg/kg) | 1000 mg/kg          | 8 weeks | Significant increase SOD, GPx, GSH, insulin and GLP-1, HDL Significant decrease HbA1C, LDL, TG, TCF, fasting glucose |
| Badole et al., India, 2014 [17] | Rats divided into four groups: 1. Nondiabetic control, 2. Diabetic control (distilled water 10 mg/kg), 3. Glutamine 500 mg/kg, 4. Glutamine 1000 mg/kg | 500–1000 mg/kg      | 4 months | Significant decrease Fasting Plasma glucose, prevent weight loss Significant increase SOD and GSH Significant decrease MDA |
Table 2 (continued)

| Author, year, place                  | Models                                                                 | Daily dose                           | Duration | Main Outcomes                                                                 |
|--------------------------------------|-------------------------------------------------------------------------|---------------------------------------|----------|-------------------------------------------------------------------------------|
| Carlos Vinicius D. da Rosa et al., Brazil, 2015 [24] | Rats divided into six groups: 1. Control, 2. Diabetic saline, 3. Control + glutamine, 4. Diabetic + glutamine, 5. Control + glutamine dipeptide (GPD), 6. Diabetic + GPD | 248 mg/kg glutamine / 400 mg/kg GPD | 30 days  | Significant increase TC, HDL. Significant decrease TG. No significant change Fasting glucose, LDL. |
| Bataglini et al., Brazil, 2017 [21]  | Rats were divided into 8 groups: 1. Non diabetic animals, 2. Diabetic animal with no hormones or GDP, 3. Diabetic + insulin, 4. Diabetic + insulin + cortisol, 5. Diabetic + insulin + glucagon, 6. diabetic + insulin + adrenaline, 7. Diabetic + insulin + GDP, 8. Diabetic + insulin + cortisol + GDP | 200–400–1000 mg /kg                  | 0–6 min  | Significant decrease TAC, TG, postprandial glucose, prevented weight loss. |
| Medras et al., Egypt, 2017 [25]      | Rats divided into 5 groups: 1. Vehicle group, 2. Diabetic rats receiving saline, 3. Diabetic rats receiving liraglutide, 4. Diabetic rats with liraglutide and glutamine, 5. Diabetic rats with liraglutide and glutamine | 4.5 mg/kg                            | 4 weeks  | Significant increase Insulin production. Significant decrease Fasting Blood glucose. No significant change TC, TG. |

TC: total cholesterol, TG: triglyceride, IL: interleukin, GSH: glutathione, GPx: glutathione peroxidase, SOD: superoxide dismutase, TAC: total antioxidant capacity, CRP: C-reactive protein, TGF: transforming growth factor beta, TNF-α: tumor necrosis factor-alpha, GLP: glucagon-like peptide, FBS: fasting blood sugar, HDL: high density lipoprotein, LDL: low density lipoprotein, MDA: malondialdehyde.
| Author, place, year | Type of study | Subjects | Sample size | Age (years) | Daily dose | Duration | Main outcomes |
|---------------------|---------------|----------|-------------|-------------|------------|----------|---------------|
| Greenfield et al., UK, 2009 [33] | RCT | T2DM | 24 | 30–40 | 75 g glucose in 300 ml of water and 30 g glutamine in 300 ml of water | 3 separate occasions over a period of < 1 month | Significant increase GLP-1, insulin production, glucagon, GIP levels |
| Samocha-Bonet et al., Australia, 2011 [14] | Crossover study | T2DM | 15 | 40–70 | 30 g L-glutamine (Gln-30), 15 g L-glutamine (Gln-15), 100 mg sitagliptin (SIT) and 100 mg SIT plus Gln-15 (SIT + Gln-15) | 1–2 weeks | Significant reduction postprandial glucose response, Significant increase postprandial insulin response, C-peptide, postprandial glucagon concentration total GLP-1 |
| Lomivorotov et al., Russia, 2012 [31] | RCT | T1DM | 64 | Intervention: (60 ± 7) 0.4 g/kg/day of 20% solution of N(2)-L-alanyl-L-glutamine | 4 weeks | No significant change Insulin resistance, insulin sensitivity, β-cell function, fasting blood glucose, TG |
| Chang et al., Australia, 2013 [29] | RCT | T2DM | 20 | Healthy Men: (29.5 ± 3.8) T2DM Patients: (68 ± 1.1) | 7.5 or 15 g glutamine or 350 ml of 0.9% saline | 0–30 min | Significant increase GLP-1, GIP, insulin and glucagon levels Insignificant Fasting blood glucose |
| Mansour et al., Iran, 2014 [28] | RCT | T2DM | 66 | 18–65 | 30 g/d glutamine | 6 weeks | Insignificant Body weight, BMI, Fasting insulin, HOMA-IR, QUICKI, TG, Cholesterol, HDL-C, LDL-C, CRP |
| Author, place, year | Type of study            | Subjects | Sample size | Age (years) | Daily dose                                                                 | Duration | Main outcomes                                                                 |
|---------------------|--------------------------|----------|-------------|-------------|-----------------------------------------------------------------------------|----------|------------------------------------------------------------------------------|
| Samocha-Bonet et al., Australia, 2014 [26] | Crossover study          | T2DM     | 13          | 40–70       | Glutamine (1.5 gbd) + sitagliptin (100 mg/d)                                | 4 weeks  | Significant reduce postprandial glucose                                        |
|                     |                          |          |             |             |                                                                             |          | Insignificant HbA1c, Fasting plasma glucose                                  |
|                     |                          |          |             |             |                                                                             |          | Significant Increase GLP-1, HbA1c, Fasting plasma glucose                   |
| Takeuti et al., Brazil, 2014 [30] | RCT                      | T2DM     | 11          | 21–60       | 9 g palm oil and 30 g glutamine diluted in 200 ml of water                  | 2 separate days | Significant reduce in palm oil group                                        |
|                     |                          |          |             |             |                                                                             |          | BG and PYY "in 2 h after the stimulus", GLP-1 "in 1 h after the stimulus" |
|                     |                          |          |             |             |                                                                             |          | Insignificant in palm oil group                                             |
|                     |                          |          |             |             |                                                                             |          | Significant increase in glutamine group                                     |
|                     |                          |          |             |             |                                                                             |          | BG "in 2 h after the stimulus"                                              |
|                     |                          |          |             |             |                                                                             |          | "Insignificant in glutamine group"                                          |
|                     |                          |          |             |             |                                                                             |          | "BG and PYY "in 1 h after the stimulus", GLP-1 "in 2 h after the stimulus" |
|                     |                          |          |             |             |                                                                             |          | Significant increase in glutamine group                                     |
|                     |                          |          |             |             |                                                                             |          | BG "in 1 h after the stimulus"                                              |
|                     |                          |          |             |             |                                                                             |          | "Insignificant in glutamine group"                                          |
|                     |                          |          |             |             |                                                                             |          | "BG and PYY "in 1 h after the stimulus", GLP-1 "in 1&2 h after the stimulus" |
| Samocha-Bonet et al., Australia, 2015 [27] | Randomized crossover study | T2DM     | 10          | 40–70       | L-glutamine (25 g), protein (25 g) or water                                  | 1–2 weeks | Significant reduce postprandial glycaemia                                     |
|                     |                          |          |             |             |                                                                             |          | Significant increase in protein group                                       |
|                     |                          |          |             |             |                                                                             |          | First-phase insulin, total GLP-1, Second-phase insulin response was significantly augmented by protein |
|                     |                          |          |             |             |                                                                             |          | Significant increase in glutation group                                     |
|                     |                          |          |             |             |                                                                             |          | Total GLP-1                                                                  |
| Meek et al. UK, 2016 [34] | Crossover study         | Healthy and T2DM | 37          | 22–30       | 3–6 g Ileal release glutamine                                               | 4 h      | Insignificant change GLP-1, insulin, glucose tolerance                        |
| Torres-Santiago, USA, 2017 [32] | Crossover study         | T1DM     | 13          |             | Drink containing 0.25 mg/kg glutamine                                       | 4 weeks  | Significant reduce Fasting Blood glucose                                     |
|                     |                          |          |             |             |                                                                             |          | Insignificant change                                                         |
|                     |                          |          |             |             |                                                                             |          | Insulin sensitivity, plasma GLP-1, basal plasma free insulin concentration   |

GLP-1: Glucagon-like peptide-1
GIP: Gastric inhibitory polypeptide
BG: Blood sugar
PYY: Peptide YY
FBS: Fasting Blood Sugar
TG: Triglyceride
TC: Total Cholesterol
HDL: High density lipoprotein
LDL: Low density lipoprotein
WC: Waist circumference
BMI: Body mass index
HOMA-IR: Homeostatic Model Assessment-Insulin Resistance Index
QUICKI: Quantitative Insulin Sensitivity Check Index
induction of diabetes by STZ. Although high dose supplementation of glutamine at 500 or 1000 mg/kg caused prevention of weight loss, no significant weight loss or gain was reported in these studies.

**Human clinical trials**

Obesity, especially central adiposity, is involved in diabetes pathogenesis via insulin resistance [35, 36]. Several main mechanisms were suggested by which obesity mediates insulin resistance, including altered secretion patterns of adipocytokines, increased levels of glucocorticoids in visceral fat tissue, and increased secretion of pro-inflammatory agents [35, 37]. Hence, weight loss with a focus on reducing central adiposity is one of the main priorities in management of diabetes. Mansour et al. examined supplementation of 30 g/d glutamine over 6 weeks in patients with T2DM and found that glutamine caused a significant reduction in body fat mass, percentage of body fat, and waist circumference, and a significant increase in fat-free mass, despite having no effect on overall body weight [28]. Samocha-Bonet et al. evaluated various doses of glutamine (15 g/d for 4 weeks and 25 g/d for 1–2 weeks); the results of their studies showed no significant changes in body weight [26, 27].

**Glutamine and glycemic status in diabetes mellitus**

**Animal studies**

All included studies assessed the possible effect of glutamine on glycemic status in diabetic animals. However, due to the different duration of supplementation and the wide range of glutamine dosage, contradiction was observed in the results. Glutamine supplementation with three different dosages (250–500–1000 mg/kg) resulted in a significant reduction in plasma glucose level, with an increase in plasma and pancreatic levels of insulin [18]. In the most recent study conducted on this subject, 4 weeks of supplementation of 4.5 mg/kg glutamine caused a significant increase in insulin production and a decrease in glucose levels [25]. A significant reduction was observed in glucose blood level following a 4-week glutamine supplementation regime [32]. A high-dose glutamine supplementation led to postprandial glucose reduction [27]. In contrast, almost half of included studies showed no statistically significant improvement in glycemic status [19, 20, 22–24, 26, 29, 31].

**Human clinical trials**

The effects of glutamine on hormone secretion and pyloric motility seem to conform in a dose-dependent manner [36]. Mansour et al. indicated that 30 g/d glutamine for 6 weeks substantially decreased FBS and Hb A1c in patients with T2DM; however, there were no significant changes in fasting insulin and insulin sensitivity index between groups [37]. Also, oral dose of encapsulated glutamine did not stimulate consistent increase in GLP-1 and insulin secretion in type 2 diabetes patients [34]. In a study by Greenfield et al., healthy, obese subjects with T2DM or impaired glucose tolerance received oral glucose (75 g), glutamine (30 g).

In another study by Samocha-Bonet et al., T2DM patients consumed 15 g glutamine with 100 mg/d sitagliptin or 15 g glutamine with a placebo [38]. After 4 weeks, L-glutamine decreased HbA1c and fructosamine irrespective of sitagliptin in patients with T2DM, and postprandial glucose decreased with significant time-treatment interactions, while HbA1c and fructosamine decreased without significant time-treatment interactions [38]. Samocha-Bonet et al. reported reduced early postprandial glycemia in patients with T2DM after administration of a single dose of 30 g of glutamine or 15 g glutamine with or without sitagliptin [39]. Glutamine at both dosages significantly increased postprandial insulin response and glucagon levels; however, C-peptide levels were not affected [28]. In contrast, 4 weeks of glutamine supplementation (0.4 g/kg) did not show any significant changes in insulin resistance, insulin sensitivity, β-cell function, or blood glucose in patients with T1DM [31]. Also, administering 0.25 g/kg glutamine to adolescents did not change glycemic parameters such as insulin sensitivity or basal plasma free insulin concentration, except for blood glucose after 4 weeks in patients with T1DM [32]. This may, however, be due to the low dose of glutamine.

**Glutamine and incretin hormones in diabetes mellitus**

**Animal studies**

Incretin hormones trigger physiological pathways to release insulin following a meal [38]. Some evidence suggests hyperglycemic state decreases GLP-1 secretion in T2DM [39, 40]. Glutamine may stimulate GLP-1–secreting cells to release GLP-1 [41]. Two of the studies in which incretin hormones were evaluated showed a significant increase in GLP-1 after 8 weeks of high-dose glutamine supplementation.

**Human clinical trials**

Glutamine significantly increased GLP-1 compared to water alone. Elevation of circulating GLP-1 levels following the ingestion of glutamine was detectable as early as 15 min post-ingestion. Glutamine also caused a significant increase in plasma insulin levels, particularly in obese subjects; however, glucagon levels also increased. GIP levels increased following glutamine consumption; however, the effectiveness was less than that of glucose [35].
The mechanism by which glutamine influences glycemic status may be explained by GLP-1–induced slowing of gastric emptying [28]. Chang et al. evaluated intraduodenal (ID) infusions of glutamine (7.5 or 15 g) or saline over 30 min in healthy subjects and 15 g glutamine or saline in T2DM patients followed by an ID infusion of glucose over 100 min [36]. The results showed that 15 g ID glutamine significantly enhanced GLP-1 and glucagon concentrations with modest increments in insulin levels and phasic pyloric pressures in both groups [36]. Glutamine infusion significantly stimulated GIP only in T2DM patients, while the glucose load was not decreased, likely due to elevated levels of glucagon [36].

The changes of active GLP-1 and insulin-to-glucose AUC were also incremental with a significant time-treatment effect; however, fasting total GLP-1, fasting active GLP-1, and postprandial total GLP-1 increased without a significant time-treatment interaction [38]. In a study by Takeuti et al., T2DM patients consumed 30 g of glutamine diluted in 200 ml of water for one day, and the authors observed a significant reduction in blood glucose 2 h after the ingestion of glutamine; however, blood glucose 1 h afterward and PYY and GLP-1, 1 and 2 h after glutamine consumption showed no significant changes. Samocha-Bonet also examined the effect of oral L-glutamine [25 g], whole protein low in glutamine (25 g), or water on the concentration of incretin hormones and insulin response in well-controlled T2DM patients and found that the first-phase insulin response and total GLP-1 were enhanced following the ingestion of both L-glutamine and protein; however, only protein potentiated the second-phase insulin response [27].

Glutamine and lipid profile in diabetes mellitus

Animal studies
Among the included studies, six examined the possible effect of glutamine on lipid parameters. Eight weeks of administering 1gr/kg glutamine resulted in a significant reduction in LDL, TC, and TG levels, and a significant improvement in HDL levels [18]. Three other studies showed a reduction in TG levels after glutamine supplementation; however, no statistically meaningful change was observed on other lipid parameters, including LDL, TC, and HDL [21, 23, 24]. In addition, Tsai et al. found no significant changes after glutamine supplementation on the lipid profile [19]. Although most included studies support the useful effects of glutamine on TG levels, it is premature to reach a specific conclusion for other parameters.

Human clinical trials
Only two human studies evaluated the effect of glutamine on the lipid profile, and neither resulted in a significant change. 30 g/day for 6 weeks showed no significant changes in LDL, HDL, TG, or TC levels [28].

Glutamine and oxidative stress and inflammation biomarkers in diabetes mellitus

Animal studies
Seven studies evaluated the effects of glutamine on oxidative stress and inflammatory biomarkers. Glutamine dosage was between 250 to 1000 mg/kg among the studies, and supplementation duration was from 15 days to 4 months. Three studies conducted by Badole et al. showed a significant reduction in oxidative stress, which resulted from an improvement in SOD, MDA, GSH, TAC, and CAT after supplementation with three different dosages (250–500–1000 mg/kg) of glutamine for over two months [17, 18]. In another study, 1000 mg/kg of glutamine showed a significant increase in IL-1 and IL-6 levels after 15 days. Tsia et al. found that supplementing glutamine for 6–8 weeks led to a reduction of CRP, IL-23, IL-6, and MCP-1 levels. However, no changes were observed in TGF-β, TNF-α, or IL-17A [19, 20, 22].

Human clinical trials
In the only human study that evaluated the effect of glutamine of inflammatory markers, Mansour et al. found no significant change in CRP after supplementing 30 g/day glutamine for 6 weeks [28].

Discussion
The results of this systematic review showed that glutamine supplementation has a potential effect on improving fasting plasma glucose [17, 18, 22, 25, 28, 29, 31, 32], postprandial blood glucose [14, 21, 26, 27, 30], and significant increases in insulin production and incretin hormones such as GIP and GLP-1 [18, 26, 27, 29, 30, 33]. However, results from insulin sensitivity were contradictory [31, 32]. Regarding HbA1c and HOMA-IR, there is a lack of sufficient evidence to reach any conclusion.

Generally, incretin hormones such as GLP-1 and GIP are released from intestinal L-cells and play an essential role in physiologically mediating insulin secretion after a meal [14]. Since GLP-1 production is assumed to remain intact in well-controlled diabetic patients and stimulates insulin release and lowers postprandial glycemia, several therapeutic approaches are being developed to increase GLP-1 action for treating diabetes mellitus [27]. Glutamine, a nonessential amino acid, is the most common free amino acid found in body fluids and skeletal muscles and has a pivotal role in regulating cell proliferation and growth [30] as well as stimulating incretin hormones, particularly GLP-1 secretion [15]. Interestingly, significant reductions in glutamine concentration have been
found in diabetes mellitus compared with healthy individuals [28]. Nevertheless, studies have shown significant increases in GLP-1 levels following additional glutamine administration in diabetes mellitus [26, 27, 42].

Different mechanisms for glutamine signaling pathways should be taken into account. First, glutamine uptake with GLUTage cells is sodium-dependent, which could itself initiate GLP-1 secretion [33]. Indeed, in vitro and epidemiological studies have demonstrated elevated effects of glutamine on GLP-1 secretion in GLUTage cells more than other amino acids and even glucose [15, 41]. In this context, one in vitro study has found that glutamine causes membrane depolarization initiation and, subsequently, calcium entry into cells, which ultimately leads to GLP-1 secretion [14]. In addition, the effects of glutamine on lowering glucose levels could be due to two different GLP-1-dependent mechanisms, including possibly stimulating insulin secretion or, more likely, slowing the gastric emptying rate [29]. In this regard, in healthy subjects, having a mixed meal, a combination of protein, carbohydrates, and fat, followed by a higher energy expenditure, prolonged the rate of gastric emptying and resulted in lower glyemia compared with a meal of carbohydrates alone [14]. Additionally, GLP-1 regulates insulin secretion from pancreas β-cells in both normal and disease conditions [27]. Likewise, glutamine, through GLP-1 mediation and in a dose-dependent manner, increases insulin release in diabetes mellitus [29]. An in vivo study on a high fat diet enriched with glutamine administered to Wistar rats found that glucose uptake increased with stimulation of insulin signaling in skeletal muscles and reduced hepatic gluconeogenesis, which both showed improvement in insulin sensitivity [43].

Dyslipidemia is one of the major complications of diabetes mellitus; thus, reducing lipid profile parameters may play a protective role in cardiovascular disease. Results demonstrated significant reductions in TG levels after glutamine administration [18, 21, 24]. However, the findings on TC, LDL, and HDL were contradictory [18, 19, 23, 24, 28]. Additionally, no significant change was observed in human studies, and the results were insufficient to draw any conclusions [28]. Hyperglycemia causes a significant increase in lipid profile levels, which may be related to a lack of insulin. The normalization of glycemic status is shown to have a significant effect on the lipid profile. Glutamine could have a lipid-lowering effect by increasing GLP-1 secretion. Increased levels of GLP-1 are associated with a reduction in lipid absorption [18]; in addition, it appears that GLP-1 can directly reduce hepatic lipogenesis and expression of lipogenesis-related genes through the cAMP/AMPK pathway [44]. In another study, GLP-1 was able to decrease lipid accumulation in the absence of insulin [45].

Anthropometric data derived from the studies is inadequate, although glutamine prevented weight loss after diabetes induction in animals [17, 21]. Although trunk fat, total fat, and total fat-free mass were all significantly decreased, no significant changes were observed in BMI or body weight in human studies [28]. Obesity is a well-known modifiable risk factor for diabetes that can be managed by nutritional therapy [33]. It has been suggested that additional glutamine intake has anti-obesity as well as antidiabetic properties [46]. A hypothesized mechanism is attributed to L-cells that co-produce GLP-1 and GLP-2 at the same time, which regenerates intestinal epithelium, mediates peptide YY production, and subsequently, through appetite suppression, prolongs satiety through GLP-1 receptors and thus manages weight control [33, 47].

Changes in body composition are a common feature in diabetic patients with abnormal decreases in lean body mass, particularly in elderly individuals [28]. Concerning this deterioration, in vivo evidence has demonstrated the protective role of glutamine on reducing fat mass (FM) and waist circumference (WC) as well as increasing fat-free mass (FFM) without significant changes in body weight [28]. It is possible that glutamine, by increasing GLP-1 levels, which mediate FM and body weight reduction or replace FM with muscle, improves body composition in diabetes mellitus [28]. GLP-1 also affects adipose tissue, leading to increased lipolysis and thermogenesis in brown adipose tissue [48, 49]. Given the beneficial effects of glutamine on GLP-1, it is recommended to conduct clinical trials on the effects of glutamine on the expression of the genes involved in lipogenesis and thermogenesis in fat tissues. Studies have shown that GLP-1 leads to the suppression of the appetite center in the central nervous system, and a decrease in the secretion of the ghrelin hormone and gastric emptying [50, 51]. On the other hand, glutamine can lead to an increase in serum levels of GLP-1. Therefore, it is recommended the effect of glutamine on hormones involved in appetite, especially ghrelin, should be considered in future directions.

Results suggest a potential effect of glutamine on oxidative stress and inflammatory markers. Glutamine supplementation showed a significant increase in SOD, GSH, GPx, and catalase in animal studies [17–20, 22] as well as meaningful alleviations in CRP, IL-6, IL-23, and MCP-1 levels [22]. Glutamine may have an antioxidant effect due to its role in glutathione synthesis. It can increase the enzyme activity of glutathione peroxidase and reduce ROS production [17, 18]. Thus, it can increase the total antioxidant level and activity of SOD and catalase enzymes. It is similarly indicated that oxidative stress may lead to inflammation through an increase in gene expression of NF-κB and inflammatory biomarkers.
Since oxidative stress and inflammation play a vital role in pathogenesis and side effects of diabetes, glutamine may help improve the glycemic status and ameliorate side effects of diabetes, due to its antioxidant and anti-inflammatory effects [54]. Overall, possible and potential roles of glutamine on the metabolic state in diabetes mellitus are shown in Fig. 2.

**Conclusion**

This systematic review found that glutamine supplementation can lead to a decrease in fasting blood glucose, post-meal glucose, and triglyceride levels and an increase in insulin production. However, the results on the effect of glutamine on Hb-A1c and TC, LDL, and HDL levels were inconclusive. Glutamine supplementation also resulted in increased levels of GLP-1.

Although the outcomes seem promising for the effects of glutamine on weight changes, oxidative stress, and inflammation, more precise clinical trials are needed to obtain more accurate results.

**Acknowledgments**

The study is supported financially by Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran (No: 61801). The study proposal was approved by Medical Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.VCR.REC.1397.366).

**Authors’ contributions**

HJ: contributed to the study conception, design, and data collection and drafting of the manuscript. PV: contributed to the study conception, design, and data collection and drafting of the manuscript. FH: participated in data collection and interpretation, writing the manuscript. HR: participated in data collection and interpretation, writing the manuscript. MA: contributed to the interpretation of data, revising the paper critically, and giving final approval. VM: participated in study design, revising the paper, and approving the version of the manuscript being submitted. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. 2 Faculty of Health, Arak University of Medical Sciences, Arak, Iran. 3 Departments of Chemistry and Biochemistry, and Biology and Biomolecular Sciences Program, Laurentian University, Sudbury, ON, Canada. 4 Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran. 5 Nutrition Research Center, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Received: 27 November 2019   Accepted: 10 September 2020
Published online: 25 September 2020

References
1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88.
2. Atlas ID. International Diabetes Federation, 7th edn; 2015.
3. Cho N, Shaw J, Karuranga S, Huang Y, da Rocha FJ, Ohhrogge A, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.
4. Oouuoyu J, Obima K, Belonuwa C, Unakalamba C. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013;4(4):46–57.
5. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:S5.
6. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement 1):S81–90.
7. Papatheodorou K, Papanas N, Banach M, Papazoglu D, Edmonds M. Complications of diabetes 2016. J Diabetes Res. 2016;2016:6989453.
8. Dominguei CP, Duus LMSA, da Graças Carvalho M, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complicat. 2016;30(4):738–45.
9. Colberg SR, Sigal RJ, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care. 2010;33(12):e147–67.
10. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev. 1990;48(8):297–309.
11. Xiao D, Zeng L, Yao K, Kong X, Wu G, Yin Y. The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications. Amino Acids. 2016;48(9):2067–80.
12. da Silva KM, de Bittencourt PIH. Type 1 diabetes: can exercise impair the autoimmune event? The L-arginine/glutamine coupling hypothesis. Cell Biochem Funct. 2008;26(4):406–33.
13. Molfino A, Logorelli F, Muscartoli M, Cascino A, Preziosa I, Fanelli FR, et al. Metabolic effects of glutamine on insulin sensitivity. Nutr Ther Metab. 2010;28:7.
14. Samocha-Bonet D, Chisholm DJ, Gribble FM, et al. Glutamine reduces postprandial glycemia and augments the ingestion of the palm oil and glutamine in serum levels of GLP-1, PYY and glucose in diabetes mellitus type 2 patients submitted to metabolic surgery. Braz Arch Digest Surg. 2014;27(Suppl 1):S1–S.
15. Lomivorotov VV, Efremov SM, Shmirev VA, Ponomarev DN, Syvatchenko YM, Deryagin YM. Glutamine up-regulates pancreatic sodium-dependent neutral aminoacid transporter-2 and mitigates islets apoptosis in diabetic rats. Pharmacol Rep. 2018;70(2):233–42.
16. Badole SL, Chaudhari SM, Bagul PP, Mahamuni SP, Khose RD, Joshi AC, et al. Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7–36) amide secretion, biochemical and oxidative stress in streptozotocin-nicotinamide induced diabetic sprague dawley rats. PLoS ONE. 2013;8(8):e72917.
38. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–39.
39. Laakso M, Zilinskiene J, Hansen T, Boesgaard TW, Vanttininen M, Stancakova A, et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia. 2008;51(3):502–11.
40. Vollmer K, Gardiwal H, Menge BA, Goetze O, Deacon CF, Schmidt WE, et al. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab. 2009;94(4):1379–85.
41. Reimann F, Williams L, da Silva XG, Rutter GA, Gribble FM. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia. 2004;47(9):1592–601.
42. Andersson LE, Shcherbina L, Al‑Majdoub M, Vishnu N, Arroyo CB, Carrara JA, et al. Glutamine‑elicited secretion of glucagon‑like peptide 1 is governed by an activated glutamate dehydrogenase. Diabetes. 2018;67(3):572–84.
43. Prada P, Hirabara S, De Souza C, Schenka A, Zecchin H, Vassallo J, et al. RETRACTED ARTICLE: L‑glutamine supplementation induces insulin resistance in adipose tissue and improves insulin signalling in liver and muscle of rats with diet‑induced obesity. Diabetologia. 2007;50(9):1949–59.
44. Ben‑Shlomo S, Zvibel I, Shnall M, Shlomai A, Chepurko E, Halpern Z, et al. Glucagon‑like peptide‑1 reduces hepatic lipogenesis via activation of AMP‑activated protein kinase. J Hepatol. 2011;54(6):1214–23.
45. Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurt JM, Gathercole LL, et al. Glucagon‑like peptide 1 decreases lipotoxicity in non‑alcoholic steatohepatitis. J Hepatol. 2016;64(2):399–408.
46. Optra EC, Petro A, Tevzian A, Feinglos MN, Survit RS. L‑glutamine supplementation of a high fat diet reduces body weight and attenuates hyperglycemia and hyperinsulinemia in C57BL/6j mice. J Nutr. 1996;126(1):273–9.
47. Joo E, Muraoka A, Hamaaki A, Harada N, Yamane S, Kondo Y, et al. Enteral supplementation with glutamine, fiber, and oligosaccharide modulates incretin and glucagon‑like peptide‑2 secretion. J Diabetes Investig. 2015;6(3):302–8.
48. Xu F, Lin B, Zheng X, Chen Z, Cao H, Xu H, et al. GLP‑1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia. 2016;59(5):1059–69.
49. Romanelli MMC, Vianello E, Malavazos AE, Tacchini L, Schmitz G, Iacobellis G, et al. GLP‑1 receptor is associated with genes involved in fatty acids oxidation and white‑to‑brown fat differentiation in epicardial adipose tissue (EAT). FASEB J. 2019;33(1_supplement):662.21.
50. De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP‑1 as therapeutic targets in obesity. Gut Liver. 2012;6(1):10.
51. Shah M, Vella A. Effects of GLP‑1 on appetite and weight. Rev Endocr Metab Disorders. 2014;15(3):181–7.
52. Marques C, Mauriz JL, Simonetto D, Marroni CA, Turhon MJ, Gonzalez‑Gallego J, et al. Glutamine prevents gastric oxidative stress in an animal model of portal hypertension gastropathy. Ann Hepatol. 2016;10(4):531–9.
53. Aboud OA, Habib SL, Trott J, Stewart B, Liang S, Chaudhari AJ, et al. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real‑time imaging. Can Res. 2017;77(23):6746–58.
54. Mahdavifard S, Nakhjavan M. Effect of glutamine on oxidative stress, inflammatory, and glycation markers, and the activity of glyoxalase system in diabetic rats with atherosclerosis. J Mazandaran Univ Med Sci. 2019;28(170):33–42.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.